Preventing tuberculosis in children receiving anti-tnf treatment

Clinical Rheumatology

Volumn 29, Issue 4, 2010, Pages 389-392

  Ayaz, Nuray Aktay ^a   Demirkaya, Erkan ^b   Bilginer, Yelda ^b   Özçelik, Uǧur ^b   Çobanoǧlu, Nazan ^b   Kiper, Nural ^b   Besbas, Nesrin ^b   Bakkaloǧlu, Aysin ^b   Özen, Seza ^b  

^a ACIBADEM UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anti TNF; Juvenile idiopathic arthritis; Tuberculosis

Indexed keywords

BCG VACCINE; ETANERCEPT; ISONIAZID; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BCG VACCINATION; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LUNG TUBERCULOSIS; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCREENING; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TURKEY (REPUBLIC);

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MASS SCREENING; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; TURKEY; YOUNG ADULT;

EID: 77950861826     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1334-5     Document Type: Article

References (33)

1. LS Peterson T Mason AM Nelson WM O'Fallon SE Gabriel 1996 Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993: is the epidemiology changing? Arthritis Rheum 39 1385 1390 10.1002/art.1780390817 1:STN:280:DyaK28zitVansA%3D%3D 8702448 (Pubitemid 26270099)
2. RE Petty P Malleson 1987 Epidemiology of juvenile rheumatoid arthritis World Pediatr Child Care 3 205 10
3. G Gartlehner RA Hansen BL Jonas BL Jonas P Thieda KN Lohr 2008 Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of evidence Clin Rheumatol 27 67 76 10.1007/s10067-007-0654-6 17570009 (Pubitemid 350182680)
4. CA Wallace 2006 Current management of juvenile idiopathic arthritis Best Pract Res Clin Rheumatol 20 279 300 10.1016/j.berh.2005.11.008 16546057
5. DJ Lovell EH Giannini A Reiff, et al. 2000 Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group N Eng J Med 342 763 9 10.1056/NEJM200003163421103 1:CAS:528:DC%2BD3cXit1Smu7k%3D (Pubitemid 30151920)
6. KM Mohler DS Torrance CA Smith, et al. 1993 Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1548 1561 1:CAS:528:DyaK3sXmtVWmsL4%3D 8393046
7. T Hehlgans K Pfeffer 2005 The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games Immunology 115 1 20 10.1111/j.1365-2567.2005.02143.x 1:CAS:528: DC%2BD2MXjvFaqtrs%3D 15819693 (Pubitemid 40598088)
8. K Pfeffer 2003 Biological functions of tumor necrosis factor cytokines and their receptors Cytokine Growth Factor Rev 14 185 91 10.1016/S1359-6101(03) 00022-4 1:CAS:528:DC%2BD3sXkt1Ghsr0%3D 12787558 (Pubitemid 36693140)
9. SB Desai DE Furst 2006 Problems encountered during anti-tumour necrosis factor therapy Best Pract Res Clin Rheumatol 20 757 90 10.1016/j.berh.2006.06. 002 1:CAS:528:DC%2BD28Xps1Cntb8%3D 16979537 (Pubitemid 44350122)
10. MA Gardam EC Keystone R Menzies, et al. 2003 Anti-tumour necrosis factor agents and tuberculosis risk: mechanism of action and clinical management Lancet Infect Dis 3 148 55 10.1016/S1473-3099(03)00545-0 1:CAS:528: DC%2BD3sXislKmsLo%3D 12614731 (Pubitemid 36278124)
11. LP Omerod 2004 Assesing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF alpha treatment Cytokine 28 179 81 10.1016/j.cyto.2004.07.013 (Pubitemid 39573506)
12. LP Omerod 2004 Tuberculosis and anti-TNF alpha treatment Thorax 59 921 10.1136/thx.2004.029991 (Pubitemid 39490772)
13. JJ Gomez-Reino L Carmona VR Valverde EM Mola Montero MD BIOBADASER Group 2003 Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis Rheum 48 2122 7 10.1002/art.11137 1:CAS:528:DC%2BD3sXntVWgsLc%3D 12905464 (Pubitemid 36959191)
14. J Keane S Gershon RP Wise, et al. 2001 Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 1098 104 10.1056/NEJMoa011110 1:CAS:528:DC%2BD3MXnsFShsr0%3D 11596589
15. RS Wallis MS Broder JY Wong ME Hanson DO Beenhouwer 2004 Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 9 1261 5 10.1086/383317 1:STN:280:DC%2BD2c3islCksg%3D%3D 15127338 (Pubitemid 38608568)
16. R Long M Gardam 2003 Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection CMAJ 168 1153 1156 12719321 (Pubitemid 36543228)
17. J Askling M Fored L Brandt, et al. 2005 Risk and case characteristic of TB in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden Arthritis Rheum 52 1986 92 10.1002/art.21137 1:CAS:528: DC%2BD2MXnsl2gsLY%3D 15986370 (Pubitemid 40994319)
18. D Baeten E Kruithof F Van den Bosch, et al. 2003 Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62 829 34 10.1136/ard.62.9.829 1:CAS:528: DC%2BD3sXns1Sisb4%3D 12922954 (Pubitemid 37026492)
19. ATS/CDC Statement Committee on Latent TB Infection. Targeted Tuberculin Testing and Treatment of Latent TB Infection. CDC Morbidity and Mortality, 2007. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm. Accessed 21 June 2007)
20. K Dasgupta D Menzies 2005 Cost effectiveness of TB control strategies among immigrants and refugees Eur Respir J 25 1107 16 10.1183/09031936.05. 00074004 1:STN:280:DC%2BD2M3osFCntA%3D%3D 15929967 (Pubitemid 40823787)
21. American Thoracic Society(2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161:221-247
22. RS Wallis MS Broder JY Wong JY Hanson DO Beenhouwer 2004 Granulomatous infectious diseases associated with TNF antagonists Clin Infect DIs 38 1261 65 10.1086/383317 1:STN:280:DC%2BD2c3islCksg%3D%3D 15127338 (Pubitemid 38608568)
23. RS Wallis MS Broder JY Wong DO Beenhouwer 2004 Granulomatous infections due to tumor necrosis factor blockade: correction Clin Infect DIs 39 1254 56 10.1086/424455 15486857 (Pubitemid 40169331)
24. Salmon D, Tubach F, Ravaud P (2007) A risk of tuberculosis persists in patients treated with anti TNF-a antagonist therapy despite prophylactic guidelines: identification of main risk factors. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th Interntational Congress of Chemotherapy; Munich, Germany; March 31-April 3, 2007 Abstract O471
25. F Tubach D Salmon-Ceron P Ravaud X Mariette 2005 The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnF alpha therapy Joint Bone Spine 72 456 60 10.1016/j.jbspin.2005.10.004 16311059 (Pubitemid 41821398)
26. L Carmona JJ Gomez-Reino V Rodriguez-Valverde, et al. 2005 Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 1766 72 10.1002/art.21043 1:CAS:528:DC%2BD2MXlvFChur0%3D 15934089 (Pubitemid 40852885)
27. P Brassard A Kezouh S Suissa 2006 Antirheumatic drugs and the risk of tuberculosis J Infect Dis 43 1532 37 (Pubitemid 44330734)
28. G Matulis P Juni PM Villiger SD Gadola 2008 Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay Ann Rheum Dis 67 84 90 10.1136/ard.2007.070789 1:CAS:528:DC%2BD1cXhs1ejtLk%3D 17644549
29. N Cobanoglu U Ozcelik U Kalyoncu S Ozen S Kiraz N Gurcan, et al. 2007 Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers Int J Tuberc Lung Dis 11 1177 82 1:STN:280:DC%2BD2snjsFWhtw%3D%3D 17958978 (Pubitemid 350146297)
30. H Takahashi K Shigehara M Yamamoto C Suzuki Y Naishiro Y Tamura, et al. 2007 Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration Rheumatol Int 27 1143 8 10.1007/s00296-007-0361-2 1:CAS:528:DC%2BD2sXhtVSisLbP 17503048 (Pubitemid 47373944)
31. D Ponce de Leon E Acevedo-Vasquez S Alvizuri C Gutierrez M Cucho J Alfaro, et al. 2008 Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population J Rheumatol 35 776 81 18398944 (Pubitemid 351747116)
32. R Dinser M Fousse U Sester K Albrecht M Singh H Köhler, et al. 2008 Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay Rheumatology (Oxford) 47 212 8 10.1093/rheumatology/kem351 1:CAS:528:DC%2BD1cXht1Shsbw%3D (Pubitemid 351168235)
33. N Harada Y Nakajima K Higuchi Y Sekiya J Rothel T Mori 2006 Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers Infect Control Hosp Epidemiol 27 442 8 10.1086/504358 16671023 (Pubitemid 43835524)